Menu
Search
Search
Menu
Hjem
Markeder
Open submenu
Aksjer
Open submenu
Indekser
Open submenu
ETF-er
Open submenu
Fond
Open submenu
Obligasjoner
Open submenu
Strukturerte produkter
Open submenu
Derivater
Open submenu
Råvarer
Open submenu
Education
Open submenu
Ressurser
Open submenu
Close submenu
Markeder
Amsterdam
Open submenu
Brussel
Open submenu
Dublin
Open submenu
Lisboa
Open submenu
Milan
Open submenu
Oslo
Open submenu
Paris
Open submenu
Close submenu
Amsterdam
Cash Products
Open submenu
Derivater
Open submenu
Selskapsmeldinger
Open submenu
Close submenu
Cash Products
Aksjer
Open submenu
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Close submenu
Aksjer
AEX index Stocks
AEX ESG Stocks
Close submenu
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Close submenu
Selskapsmeldinger
Latest
Archive
Close submenu
Brussel
Cash products
Open submenu
Derivater
Open submenu
Selskapsmeldinger
Open submenu
Expert Market
Close submenu
Cash products
Aksjer
Open submenu
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Close submenu
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Close submenu
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Close submenu
Selskapsmeldinger
Latest
Archive
Close submenu
Dublin
Stocks
Open submenu
Indices
Funds
Bonds
Irish Government Bonds
DOL
Close submenu
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Close submenu
Lisboa
Cash Products
Open submenu
Derivater
Open submenu
Selskapsmeldinger
Open submenu
Close submenu
Cash Products
Aksjer
Open submenu
Indekser
Obligasjoner
Close submenu
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Close submenu
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Close submenu
Selskapsmeldinger
Latest
Archive
Close submenu
Milan
Cash Products
Open submenu
Derivative products
Open submenu
IPOs
Close submenu
Cash Products
Stocks
Open submenu
Bonds
Open submenu
Structured Products
Open submenu
ETFs
Funds
Close submenu
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Close submenu
Bonds
MOT
Euronext Access Milan
EuroTLX
Close submenu
Structured Products
SeDeX
EuroTLX
Close submenu
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Close submenu
Oslo
Aksjer, renter, indekser
Open submenu
Derivater
Open submenu
Selskapsmeldinger
Open submenu
Finanskalender
Primærinnsidere
Close submenu
Aksjer, renter, indekser
Aksjer
Open submenu
Aksjeindekser
Obligasjoner
Open submenu
Obligasjonsindekser
ETFer
Fond
Close submenu
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Close submenu
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Close submenu
Derivater
Derivative products
Quote Vendor Codes
Close submenu
Selskapsmeldinger
Latest
Archive
Close submenu
Paris
Cash Products
Open submenu
Derivater
Open submenu
Selskapsmeldinger
Open submenu
Close submenu
Cash Products
Aksjer
Open submenu
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Close submenu
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Close submenu
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Close submenu
Selskapsmeldinger
Latest
Archive
Close submenu
Aksjer
All Markets directories
Open submenu
Selskapsmeldinger
Open submenu
Nye aksjenoteringer
Open submenu
Euronext Growth advisors
Euronext Tech Leaders
Family business
Close submenu
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Close submenu
Selskapsmeldinger
Latest
Archive
Close submenu
Nye aksjenoteringer
Alle aksjenoteringer
Close submenu
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
Close submenu
ETF-er
Directory
Grønne ETF-er
Close submenu
Fond
Directory
ESG Funds
Oslo Mutual Funds
Close submenu
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
Open submenu
Close submenu
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Close submenu
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Close submenu
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Close submenu
Råvarer
Quotes
Open submenu
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
DSP
Close submenu
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Close submenu
Education
Academy
Stocks Education
Option education
Our Indices
Educational videos
News & Insights
Close submenu
Ressurser
Statistikk & rapporter
Open submenu
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Open submenu
Notices / Corporate actions
Open submenu
Markedshendelser
Open submenu
Medlemsliste
Issuers compliance
Hvor du finner hva
Close submenu
Statistikk & rapporter
Quality of execution
Close submenu
Key Information Document
Class level
Product group level
Close submenu
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
Open submenu
Derivatives notices
Close submenu
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Close submenu
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 50 av 159 resultater
Tid
Selskap
Tittel
Sektor
Kategori
04 Mar 2025
18:00 CET
POXEL
Poxel : nombre d’actions et de droits de vote composant le capital social
20103010 Biotechnology
Other subject
19 Feb 2025
18:23 CET
POXEL
Poxel publie son chiffre d’affaires pour l’exercice 2024 et fait le point sur sa situation et ses perspectives financières
20103010 Biotechnology
Sales
19 Feb 2025
18:23 CET
POXEL
Poxel Reports Revenue for the Full Year 2024 and Provides an Update on its Financial Position and Outlook
20103010 Biotechnology
Sales
18 Feb 2025
18:24 CET
POXEL
Poxel : nombre d’actions et de droits de vote composant le capital social
20103010 Biotechnology
Other subject
11 Feb 2025
20:28 CET
POXEL
Poxel annonce les résultats de son Assemblée Générale Mixte du 11 février 2025
20103010 Biotechnology
General meeting / Board Meeting
11 Feb 2025
20:28 CET
POXEL
Poxel Announces Results of its Combined General Meeting Held on February 11, 2025
20103010 Biotechnology
General meeting / Board Meeting
31 Jan 2025
07:30 CET
POXEL
Poxel’s partner Sumitomo Pharma reports TWYMEEG® gross sales in Japan for Q4 2024 and FY 2024 sales forecast
20103010 Biotechnology
Other subject
31 Jan 2025
07:30 CET
POXEL
Poxel publie les ventes brutes de TWYMEEG® au Japon pour le quatrième trimestre 2024 et les prévisions de vente pour l'exercice 2024 annoncées par son partenaire Sumitomo Pharma
20103010 Biotechnology
Other subject
23 Jan 2025
18:00 CET
POXEL
Poxel annonce son agenda financier pour l’exercice 2025
20103010 Biotechnology
Other subject
23 Jan 2025
18:00 CET
POXEL
Poxel Announces its Financial Calendar for 2025
20103010 Biotechnology
Other subject
21 Jan 2025
18:00 CET
POXEL
Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025
20103010 Biotechnology
Other subject
21 Jan 2025
18:00 CET
POXEL
Poxel : Assemblée générale ordinaire et extraordinaire du 11 février 2025
20103010 Biotechnology
Other subject
20 Jan 2025
18:00 CET
POXEL
Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment
20103010 Biotechnology
Other subject
20 Jan 2025
18:00 CET
POXEL
Poxel annonce la délivrance d’un brevet en Chine protégeant l’utilisation de l’Imeglimine chez les patients diabétiques de type 2 atteints d’insuffisance rénale
20103010 Biotechnology
Other subject
20 Jan 2025
07:30 CET
POXEL
Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan
20103010 Biotechnology
Other subject
20 Jan 2025
07:30 CET
POXEL
Poxel annonce l’atteinte des 5 milliards de yens de ventes nettes de TWYMEEG® au Japon, entraînant le versement par Sumitomo Pharma au cours du 1er trimestre 2025 d’un paiement basé sur les ventes et de redevances plus élevées
20103010 Biotechnology
Other subject
17 Jan 2025
18:00 CET
POXEL
POXEL : Bilan semestriel du contrat de liquidité contracté avec ODDO BHF SCA
20103010 Biotechnology
Other subject
09 Jan 2025
18:00 CET
POXEL
Poxel : nombre d’actions et de droits de vote composant le capital social
20103010 Biotechnology
Other subject
23 Dec 2024
07:30 CET
POXEL
Availability of Poxel’s 2024 Half-Year Financial Report
20103010 Biotechnology
Other subject
23 Dec 2024
07:30 CET
POXEL
Mise à disposition du rapport financier semestriel 2024 de Poxel
20103010 Biotechnology
Other subject
09 Dec 2024
07:30 CET
POXEL
Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook
20103010 Biotechnology
Income
09 Dec 2024
07:30 CET
POXEL
Poxel publie ses résultats financiers pour le premier semestre 2024 et fait le point sur sa situation et ses perspectives financières
20103010 Biotechnology
Income
06 Dec 2024
18:00 CET
POXEL
Poxel : nombre d’actions et de droits de vote composant le capital social
20103010 Biotechnology
Other subject
29 Nov 2024
07:30 CET
POXEL
Poxel annonce les résultats de son Assemblée Générale Mixte du 28 novembre 2024
20103010 Biotechnology
General meeting / Board Meeting
29 Nov 2024
07:30 CET
POXEL
Poxel Announces Results from November 28, 2024 Annual General Meeting
20103010 Biotechnology
General meeting / Board Meeting
07 Nov 2024
07:30 CET
POXEL
Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents
20103010 Biotechnology
General meeting / Board Meeting
07 Nov 2024
07:30 CET
POXEL
Poxel annonce la tenue de son Assemblée Générale le 28 novembre 2024 à 9h00 et la mise à disposition des documents préparatoires
20103010 Biotechnology
General meeting / Board Meeting
06 Nov 2024
18:20 CET
POXEL
Poxel publie sa trésorerie et son chiffre d’affaires pour le troisième trimestre et les neuf premiers mois de 2024 et dresse un bilan de ses activités
20103010 Biotechnology
Sales
06 Nov 2024
18:20 CET
POXEL
Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update
20103010 Biotechnology
Sales
04 Nov 2024
20:05 CET
POXEL
Poxel : nombre d’actions et de droits de vote composant le capital social
20103010 Biotechnology
Other subject
14 Oct 2024
18:00 CEST
POXEL
Poxel : nombre d’actions et de droits de vote composant le capital social
20103010 Biotechnology
Legal
14 Oct 2024
08:53 CEST
POXEL
Poxel : mise à disposition du Document d’Enregistrement Universel 2023
20103010 Biotechnology
Legal
11 Oct 2024
07:30 CEST
POXEL
Poxel Announces Availability of the 2023 Universal Registration Document
20103010 Biotechnology
Legal
03 Oct 2024
18:30 CEST
POXEL
Poxel publie ses résultats financiers pour l'année 2023 et dresse un bilan de ses activités
20103010 Biotechnology
Income
03 Oct 2024
18:30 CEST
POXEL
Poxel Reports Financial Results for Full Year 2023 and Provides Corporate Update
20103010 Biotechnology
Income
01 Oct 2024
18:00 CEST
POXEL
Poxel annonce son agenda financier pour l’exercice 2024
20103010 Biotechnology
Other subject
01 Oct 2024
18:00 CEST
POXEL
Poxel Announces its Financial Calendar for 2024
20103010 Biotechnology
Other subject
30 Sep 2024
07:30 CEST
POXEL
Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million
20103010 Biotechnology
Other subject
30 Sep 2024
07:30 CEST
POXEL
Poxel annonce un accord avec OrbiMed pour monétiser une partie des redevances issues des ventes de TWYMEEG® à hauteur de 50 millions de dollars
20103010 Biotechnology
Other subject
09 Sep 2024
07:30 CEST
POXEL
Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update
20103010 Biotechnology
Sales
09 Sep 2024
07:30 CEST
POXEL
Poxel publie son chiffre d'affaires pour le deuxième trimestre et le premier semestre 2024 et dresse un bilan de ses activités
20103010 Biotechnology
Sales
02 Sep 2024
18:00 CEST
POXEL
Poxel : nombre d’actions et de droits de vote composant le capital social
20103010 Biotechnology
Other subject
16 Aug 2024
08:11 CEST
POXEL
Poxel : nombre d’actions et de droits de vote composant le capital social
20103010 Biotechnology
Other subject
07 Aug 2024
08:00 CEST
POXEL
Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan
20103010 Biotechnology
Other subject
07 Aug 2024
08:00 CEST
POXEL
Sumitomo Pharma et Poxel annoncent les résultats préliminaires de l'étude clinique post-marketing de TWYMEEG® pour le traitement du diabète de type 2 au Japon
20103010 Biotechnology
Other subject
15 Jul 2024
07:30 CEST
POXEL
Poxel fait le point sur sa situation financière pour les deuxième trimestre et premier semestre 2024 et annonce le report de son Assemblée Générale Annuelle
20103010 Biotechnology
Other subject
15 Jul 2024
07:30 CEST
POXEL
Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting
20103010 Biotechnology
Other subject
16 May 2024
18:30 CEST
POXEL
Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update
20103010 Biotechnology
Sales
16 May 2024
18:30 CEST
POXEL
Poxel publie son chiffre d’affaires pour le premier trimestre 2024 et dresse un bilan de ses activités
20103010 Biotechnology
Sales
29 Apr 2024
18:00 CEST
POXEL
Poxel fait le point sur sa situation financière au premier trimestre 2024 et annonce le report de la publication de ses résultats annuels 2023
20103010 Biotechnology
Other subject
Press release
Open in new window
Sider
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Close menu
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window